Daniel L. Alkon MD
Equibles does not estimate personal net worth.
About Daniel L. Alkon MD
TAO Synergies Inc. reported in an 8-K filed June 9, 2025 that Daniel L. Alkon MD resigned as member of its Board of Director and any and all committees thereof, effective June 4, 2025. TAO Synergies Inc. reported in an 8-K filed June 9, 2025 that Daniel L. Alkon MD resigned as President and Chief Scientific Officer, effective June 4, 2025. The proxy statement of TAO Synergies Inc. reports total compensation of $812,461 for Daniel L. Alkon MD in fiscal 2022, including a base salary of $300,000. Disclosed compensation is on record for 4 fiscal years.
“I hereby resign effective as of June 4, 2025 as President and Chief Scientific Officer of Synaptogenix, Inc. and as a member of its Board of Director and any and all committees thereof.”
“I hereby resign effective as of June 4, 2025 as President and Chief Scientific Officer of Synaptogenix, Inc. and as a member of its Board of Director and any and all committees thereof.”
Affiliation history
-
TAO Synergies Inc. (TAOX)
Proxy statement
Start not stated–2025-06-04
Company network
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | TAO Synergies Inc. (TAOX) | President and CSO | $300,000 | $812,461 |
| 2021 | TAO Synergies Inc. (TAOX) | President and CSO | $325,000 | $1,496,028 |
| 2020 | TAO Synergies Inc. (TAOX) | President and CSO | $300,000 | $335,976 |
| 2019 | TAO Synergies Inc. (TAOX) | President and CSO | $275,000 | $801,056 |